Medical therapy of endocrine carcinomas. Part I: Thyroid carcinomas, adrenal carcinomas and parathyroid carcinomas;Medikamentose therapie endokriner karzinome. Teil I: Schilddrusenkarzinome, nebennierenkarzinome und nebenschilddrusenkarzinome

Medizinische Klinik

Volumn 95, Issue 1, 2000, Pages 20-25

  Schott, Matthias ^a   Scherbaum, Werner A ^b   Feldkamp, Joachim ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b NONE

Author keywords

Adrenal carcinoma; Chemotherapy; Endocrine carcinomas; Immunotherapy; Parathyroid carcinoma; Thyroid carcinoma

Indexed keywords

ACLARUBICIN; ALPHA INTERFERON; AMINOGLUTETHIMIDE; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; KETOCONAZOLE; METYRAPONE; MITOTANE; OCTREOTIDE; PAMIDRONIC ACID; PHENOXYBENZAMINE; VINCRISTINE; VINDESINE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADRENAL CORTEX CARCINOMA; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURGERY; ENDOCRINE TUMOR; HUMAN; PARATHYROID CARCINOMA; PHEOCHROMOCYTOMA; REVIEW; THYROID CARCINOMA; ADRENAL TUMOR; GERMANY; INCIDENCE; PARATHYROID TUMOR; THYROID TUMOR;

ADRENAL GLAND NEOPLASMS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GERMANY; HUMANS; INCIDENCE; MITOTANE; OCTREOTIDE; PARATHYROID NEOPLASMS; PHEOCHROMOCYTOMA; THYROID NEOPLASMS;

EID: 0034649844     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03044976     Document Type: Review

References (72)

1. Ahuja S, Ernst H. Chemotherapy of thyroid carcinoma. J Endocrinol Invest 1987;10:303-10.
2. Ain KB, Tofiq S, Taylor KD. Antineoplastic activity of Taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo. J Clin Endocrin Metab 1998 81:3650-3.
3. Ain KB. Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 1998;8:715-26.
4. Allolio B, Reincke M, Arlt W, et al. Suramin for treatment of adrenocortical carcinoma. Lancet 1989;2:277.
5. Averbuch SD. Endocrine tumors. Cancer Chemother Biol Response Modif 1992;13:493-507.
6. Averbuch SD, Steakley CS, Young RC, et al. Malignant pheochromocytoma: effective treatment with a combination ot cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 1988;109:267-73.
7. Bajetta E, Rimassa L, Carnaghi C, et al. 5-fluorouracil, dacarbazine, and epirubicin the treatment of patients with neuroendocrine tumors. Cancer 1998;83:372-8.
8. Barzon L, Fallo F, Sonino N, et al. Adrenocortical carcinoma: experience in 45 patients. Oncology 1997; 54:490-6.
9. Bates SE, Shieh CY, Mickley LA, et al. Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas. J Clin Endocrinol Metab 1991;73:18-29.
10. Bodie B, Novick AC, Pontes JE, et al. The Cleveland Clinic experience with adrenal cortical carcinoma. J Urol 1989;141:257-60.
11. Bradwell AR, Harvey TC. Control of hypercalcaemia of parathyroid carcinoma by immunisation. Lancet 1999;353:370-3.
12. Bukowski RM, Sheeler L, Cunningham J, et al. Successful combination chemotherapy for metastatic parathyroid carcinoma. Arch Intern Med 1984;144:399-400.
13. Calandra DB, Chejfec G, Foy BK, et al. Parathyroid carcinoma: biochemical and pathologic response to DTIC. Surgery 1984;96:1132-7.
14. Castleman B, Schantz A, Roth S. Parathyroid hyperplasia in primary hyperparathyroidism: a review ot 85 cases. Cancer 1976;38:1668-75.
15. Cohn K, Silverman M, Corrado J, et al. Parathyroid car1985;98:1095-100.
16. Collins MT, Skarulis MC, Bilezikian JP, et al. Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 1998;83:1083-8.
17. Decker RA, Elson P, Hogan TF, et al. Eastern Cooperative Oncology Group study 1879: mitotane and adnoma. Surgery 1991;110:1006-13.
18. Dickstein G, Shechner C, Arad E, et al. Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol Metab 1998;83:3100-3.
19. Didolkar MS, Bescher RA, Elias EG, et al. Natural history of adrenal cortical carcinoma: a clinicopathologic study of 42 patients. Cancer 1981;47:2153-61.
20. Epelbaum J, Bertherat J, Prevost G, et al. Molecular and pharmacological characterization of somatostatin receptor subtypes in adrenal, extraadrenal, and malignant pheochromocytomas. J Clin Endocrinol Metab 1995;80:1837-44.
21. Feldkamp J, Endokrine Therapie und Nachsorge beim Schilddrüsenkarzinom. Schweiz Rundsch Med Prax 1998;87:389-93.
22. Finklestein JZ, Klemperer MK, Evans A, et al. Multiagent chemotherapy for children with metastatic neuroblastoma: a report from Childrens Cancer Study Group. Med Pediatr Oncol 1979;6:179-88.
23. Grebe SKG, Hay ID. Follicular thyroid cancer. Endocrinol Metab Clin North Am 1996;24:761-801.
24. Grondal S, Cedermark B, Eriksson B, et al. Adrenocortical carcinoma. A retrospective study of a rare tumor with a poor prognosis. Eur J Surg Oncol 1990;16:500-6.
25. Hay ID. Papillary thyroid carcinoma. Endocrinol Metab Clin North Am 1990;19:545-76.
26. Hay ID, Grant CS, venHeerden JA, et al. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery 1992;112:1139-47.
27. Hay ID, Grant CS, Bergstralh EJ, et al. Unilateral total lobectomy: Is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma. Surgery 1998;124:958-66.
28. Hesketh PJ, McCaffrey RP, Finkel HE, et al. Cisplatin-based treatment of adrenocortical carcinoma. Cancer Treat Rep 1987;71:222-4.
29. Hoefnagel CA. Metaiodobenzylguanidine and somatostatin in oncology: role in the management ot neural crest tumours. Eur J Nucl Med 1994;21:561-81.
30. Hundahl SA, Fleming ID, Fremgen A, et al. Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985-1995. Cancer 1999;86:538-44.
31. Icard P, Chapuis Y, Andreassian B, et al. Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery 1992;112:972-9.
32. Invitti C, De MI, Bolla GB, et al. Effect of octreotide on catecholamine plasma levels in patients with chromaffin cell tumors. Horm Res 1993;40:156-60.
33. Janson ET, Oberg K. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 1993;32:225-9.
34. Jensen JC, Pass HI, Sindelar WF, et al. Recurrent or metastatic disease in select patients with adrenocortical carcinoma. Aggressive resection vs chemotherapy. Arch Surg 1991;126:457-61.
35. Johnson DH, Greco FA. Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (VP-16). Cancer 1986;58:2198-202.
36. Kasperlik ZA, Migdalska BM, Zgliczynski S, et al. Adrenocortical carcinoma. A clinical study and treatment results of 52 patients. Cancer 1995;75:2587-91.
37. Keiser HR, Goldstem DS, Wade JL, et al. Treatment of malignant pheochromocytoma with combination chemotherapy. Hypertension 1985;7:118-124.
38. Kim JH, Leeper RD. Treatment of anaplastic giant and spindle cell carcinoma of the thyroid gland with combination Adriamycin and radiation therapy. A new approach. Cancer 1983;52:954-7.
39. Kober F, Heiss A, Keminger K, et al. Chemotherapie hochmaligner Schilddrüsentumore. Wien Klin Wochenschr 1990;102:274-6.
40. La RR, Stein CA, Danesi R, et al. Suramin in adrenal cancer: modulation of steroid hormone production, cytotoxicity in vitro, and clinical antitumor effect. J Clin Endocrinol Metab 1990;71:497-504.
41. Lupoli G, Cascone E, Arlorta F, et al. Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon alpha-2b and octreotide. Cancer 1996;78:1114-8.
42. Luton JP, Cerdas S, Billaud L. et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990; 322:1195-201.
43. Markoe AM, Serber W, Micaily B, et al. Radiation therapy for adjunctive treatment of adrenal cortical carcinoma. Am J Clin Oncol 1991;14:170-4.
44. Nader S, Hickey RC, Sellin RV, et al. Adrenal cortical carcinoma. A study of 77 cases. Cancer 1983;52:707-11.
45. Nold R, Frank M, Kajdan U, et al. Combined treatment of metastatic endocrine tumors of the gastrointestinal tract with octreotide and interferon-alpha. Z Gastroenterol 1994;32:193-7.
46. Petursson SR. Metastatic medullary thyroid carcinoma. Complete response to combination chemotherapy with dacarbazine and 5-fluorouracil. Cancer 1988; 62: 1899-903.
47. Samonigg H, Hossfeld DK, Spehn J, et al. Aclarubicin in advanced thyroid cancer: a phase II study. Eur J Cancer Clin Oncol 1988;24:1271-5.
48. Sanders LE, Silverman M. Follicular and Hürthle cell carcinoma: predicting outcome and directing therapy. Surgery 1998;124:967-74.
49. Scherubl H, Raue F, Ziegler R. Combination chemotherapy ot advanced medullary and differentiated thyroid cancer. Phase II study. J Cancer Res Clin Oncol 1990;116:21-3.
50. Schlumberger M, Brugieres L, et al. 5-fluorouracil, doxorubicin, and cisplatin as treatment tor adrenal cortical carcinoma. Cancer 1991;67:2997-3000.
51. Schlumberger M, Ostronoff M, Bellaiche M, et al. 5-fluorouracil, doxorubicin, and cisplatin regimen in adrenal cortical carcinoma. Cancer 1988;61:1492-4.
52. Schmutzler C. Brtko J, Winzer R, et al. Functional retinoid and thyroid hormone receptors in human thyroid-carcinoma cell lines and tissues. Int J Cancer 1998;76:368-76.
53. Schmutzler C, Winzer R, Meissner WJ, et al. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun 1997;240:832-8.
54. Schreck R, Schnieders F, Schmutzler C, et al. Retinoids stimulate type [iodothyronine 5'-deiodinase activity in human follicular thyroid carcinoma cell liners. J Clin Endocrinol Metab 1994;79:791-8.
55. Schott M, Feldkamp J, Schattenberg D, et al. Dendritic cell immunotherapy in disseminated parathyroid carcinoma. Lancet 1999;353:1188-9.
56. Shane E, Bilezikian JP. Parathyroid carcinoma: a review of 62 patients. Endocr Rev 1982;3:218-26.
57. Shimaoka K, Schoenfeld DA, DeWys WD, et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985;56:2155-60.
58. Silverberg E, Boring CC, Squires TS. Cancer statistics. 1990. CA Cancer J Clin 1990;40:9-26.
59. Simon D, Koehrle J, Reiners C, et al. Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg 1998;22:569-74.
60. Simon D, Kohrle J, Schmutzler C, et al. Redifferentiation therapy of differentiated thyroid carcinoma with retinoic acid: basics and first clinical results. Exp Clin Endocrinol Diabetes 1996;104:Suppl 4:13-5.
61. Smythe GA, Edwards G, Graham P. et al. Biochemical diagnosis of pheochromocytoma by simultaneous measurement ot urinary excretion of epinephrine and norepinephrine. Clin Chem 1992;38:486-92.
62. Stein CA, LaRocca RV, Thomas R, et al. Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol 1989;7:499-508.
63. Tayler T, Specker B, Robbins J, et al. Outcome after treatment of high-risk papillary and non-Hürthle-cell follicular thyroid carcinoma. Ann Intern Med 1998; 129:622-7.
64. Tennvall J, Lundell G, Hallquist A, et al. Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Report on two protocols. The Swedish Anaplastic Thyroid Cancer Group. Cancer 1994;74:1348-54.
65. van SH, Moolenaar AJ, van SA, et al. The treatment of adrenocortical carcinoma with o,p'-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 1984;20:47-53.
66. van SH, van OA, CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma. Cancer Treat Rep 1983;67:377-9.
67. Vassilopoulou-Sellin R, Grince VF, Klein MJ. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 1993;71:3119-23.
68. Venkatesh S, Hickey RC, Sellin RV, et al. Adrenal corrical carcinoma. Cancer 1989;64:765-9.
69. Wang C, Gaz RD, Moncure AC. Mediastinal parathyroid exploration: a clinical and pathologic study of 47 cases. World J Surg 1986;11:687-95.
70. Williams SD, Birch R, Einhorn I H. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 1986;70:405-7.
71. Wu LT, Averbuch SD, Bal. DW, et al. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Canrer 1994:73:432-6.
72. Zilembo N, Buzzoni R, Eajetta E. et al. Salvage treatment after r-interferon alpha-2a in advanced neuroendocrine tumors. Acta Oncol 1993;32:245-50.